Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rutledge

Showing results (191-200 of 202) with videos related to

Pageof 21
Sort By:
Women'S Health (London, England)|September 7, 2013
Clinical implications of the Women's Ischemia Syndrome Evaluation: inter-relationships between symptoms, psychosocial factors and cardiovascular outcomesEileen M Handberg, Jo-Ann Eastwood, Wafia Eteiba, et al.
Circulation. Cardiovascular Interventions|May 6, 2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System TrialsPhilippe Généreux, David R Rutledge, Tullio Palmerini, et al.
Journal of Interventional Cardiology|September 25, 2012
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA StudyJames B Hermiller, David R Rutledge, Luis Gruberg, et al.
JACC. Cardiovascular Interventions|April 28, 2015
Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions)David E Kandzari, Annapoorna S Kini, Dimitri Karmpaliotis, et al.
JACC. Cardiovascular Interventions|December 24, 2011
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study)Mitchell W Krucoff, David R Rutledge, Luis Gruberg, et al.
Pain|March 11, 2016
A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating componentJ Hampton Atkinson, Mark A Slater, Edmund V Capparelli, et al.
Renal Failure|July 2, 2020
The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipientsSusan L Murray, Fergus E Daly, Patrick O'Kelly, et al.
Journal of General Internal Medicine|February 19, 2015
A Randomized Controlled Trial of a CPR and Intubation Video Decision Support Tool for Hospitalized PatientsAreej El-Jawahri, Susan L Mitchell, Michael K Paasche-Orlow, et al.
Leukemia|January 18, 2014
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031K R Schultz, M Devidas, W P Bowman, et al.
Leukemia|January 21, 2014
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031K R Schultz, A Carroll, N A Heerema, et al.
Pageof 21

Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Women'S Health (London, England)|September 7, 2013
Clinical implications of the Women's Ischemia Syndrome Evaluation: inter-relationships between symptoms, psychosocial factors and cardiovascular outcomesEileen M Handberg, Jo-Ann Eastwood, Wafia Eteiba, et al.
Circulation. Cardiovascular Interventions|May 6, 2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System TrialsPhilippe Généreux, David R Rutledge, Tullio Palmerini, et al.
Journal of Interventional Cardiology|September 25, 2012
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA StudyJames B Hermiller, David R Rutledge, Luis Gruberg, et al.
JACC. Cardiovascular Interventions|April 28, 2015
Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions)David E Kandzari, Annapoorna S Kini, Dimitri Karmpaliotis, et al.
JACC. Cardiovascular Interventions|December 24, 2011
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study)Mitchell W Krucoff, David R Rutledge, Luis Gruberg, et al.
Pain|March 11, 2016
A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating componentJ Hampton Atkinson, Mark A Slater, Edmund V Capparelli, et al.
Renal Failure|July 2, 2020
The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipientsSusan L Murray, Fergus E Daly, Patrick O'Kelly, et al.
Journal of General Internal Medicine|February 19, 2015
A Randomized Controlled Trial of a CPR and Intubation Video Decision Support Tool for Hospitalized PatientsAreej El-Jawahri, Susan L Mitchell, Michael K Paasche-Orlow, et al.
Leukemia|January 18, 2014
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031K R Schultz, M Devidas, W P Bowman, et al.
Leukemia|January 21, 2014
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031K R Schultz, A Carroll, N A Heerema, et al.
Pageof 21